FDA grants IND clearance for Adicet Bio's renal cell carcinoma treatment trial [Yahoo! Finance]
Adicet Bio, Inc. (NASDAQ: ACET) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma [Yahoo! Finance]
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate [Yahoo! Finance]